Table 1 Completed lifestyle randomised control trials (RCT) for cancer survivors.
From: Targeting obesity-related dysfunction in hormonally driven cancers
Study | Population | Intervention | BMI | Primary endpoint | Outcomes |
|---|---|---|---|---|---|
Breast cancer trials | |||||
WINS | Early stage BC | Fat reduction diet | All | RFS | 9.8% vs 12.4% (HR 0.78; CI 0.60–0.98) P = 0.03156 |
WHEL | Early stage BC | Diet | All | Recurrence rate death | 16.7% vs 16.9% (HR 0.96; CI 0.8–1.17) P = 0.63 10.1% vs 10.3% (HR 0.91; CI 0.72–1.15) P = 0.43157 |
DAMES | Mother-Daughter Dyads with early Stage BC | Diet + PA | 25–39.9 | Feasibility & weight loss | >5% weight loss in 21.7-39.1% of participants167 |
LISA | Node negative BC | Diet + PA | 24–50 | DFS events* | 12.9% vs 18.0% (HR 0.71; CI 0.41–1.24) P = 0.23181 |
ENERGY | Early stage BC | Diet + supervised exercise | 25–45 | Weight loss | 3.7% vs 1.3% at 24 months (P < 0.001)168 |
LEAN | Survivors of stage 0-III BC | Diet + PA | ≥25 | Weight loss | 6.4% vs 5.4% vs 2.0%** (P = 0.004, P = 0.009, P = 0.46)169 |
SUCCESS C | Her2-negative early stage BC | Diet + PA | 24–40 | DFS | No difference in DFS. HR 0.99; CI 0.76–1.28, P = 0.922182 |
Prostate cancer trials | |||||
MEAL | Localized PC | Diet | All | Time to progression | No difference detected. Adjusted HR 0.97 (CI 0.76–1.25), P = 0.84)183 |
CAPS2 | Localized PC | Diet | ≥24 | PSADT*** | 28 vs 13 months, P = 0.021184 |
Endometrial cancer trials | |||||
SUCCEED | Stage I-II EC | Diet + PA | ≥25 | Weight loss | 1.4 kg vs −4.6 kg (CI −1.09 to 0.14), P = 0.011185 |
Multiple cancer trials | |||||
RENEW | Survivors of BC, CRC, PC | Diet + PA | 25–40 | PF scale decline | −2.15 vs −4.84, P = 0.03186 |
